Chemistry:Fresolimumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TGF beta 1, 2 and 3 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6392H9926N1698O2026S44 |
| Molar mass | 144388.22 g·mol−1 |
  (what is this?) (verify) | |
Fresolimumab (GC1008) is a human monoclonal antibody[1] and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer[2][3] (kidney cancer and melanoma).
It binds to and inhibits all isoforms of the protein transforming growth factor beta (TGF-β).[2]
History
Fresolimumab was discovered by Cambridge Antibody Technology (CAT) scientists[4] and was one of a pair of candidate drugs that were identified for the treatment of the fatal condition scleroderma. CAT chose to co-develop the two drugs metelimumab (CAT-192) and fresolimumab with Genzyme. During early development, around 2004, CAT decided to drop development of metelimumab in favour of fresolimumab.[5]
In February 2011 Sanofi-Aventis agreed to buy Genzyme for US$20.1 billion.[6]
(As of June 2011) the drug was being tested in humans (clinical trials) against IPF, renal disease, and cancer.[7][8] On 13 August 2012, Genzyme applied to begin a Phase 2 clinical trial in primary focal segmental glomerulosclerosis[9] comparing fresolimumab versus placebo.
(As of July 2014), Sanofi-Aventis continue to list fresolimumab in their research and development portfolio under Phase II development.[10]
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN)". WHO Drug Information 23 (2). 2009. https://www.who.int/medicines/publications/druginformation/innlists/PLFinal101.pdf.
- ↑ 2.0 2.1 "Fresolimumab". NCI Drug Dictionary. National Cancer Institute. http://www.cancer.gov/drugdictionary/?CdrID=530302.
- ↑ "Fresolimumab". Statement on a Nonproprietary Name Adopted by the USAN Council. http://www.ama-assn.org/ama1/pub/upload/mm/365/fresolimumab.pdf.
- ↑ "A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions". Proceedings of the National Academy of Sciences of the United States of America 105 (51): 20251–6. December 2008. doi:10.1073/pnas.0807200106. PMID 19073914. Bibcode: 2008PNAS..10520251G.
- ↑ Foley, Stephen (10 February 2004). "CAT may abandon skin drug after trial results disappoint". The Independent. https://www.independent.co.uk/news/business/news/cat-may-abandon-skin-drug-after-trial-results-disappoint-569445.html.
- ↑ "Sanofi-Aventis to buy Genzyme in search for new sales". BBC News. 16 February 2011. https://www.bbc.co.uk/news/business-12477750.
- ↑ "Scientists Trigger White Fat to Become Brown Fat-Like to Treat Obesty and Type 2 Diabetes". Genetic Engineering & Biotechnology News. July 5, 2011. http://www.genengnews.com/gen-news-highlights/scientists-trigger-white-fat-to-become-brown-fat-like-to-treat-obesty-and-type-2-diabetes/81245389/.
- ↑ "Studies found for Fresolimumab". Clinicaltrials.gov. http://www.clinicaltrials.gov/ct2/results?term=Fresolimumab.
- ↑ Clinical trial number NCT01665391 for "A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)" at ClinicalTrials.gov
- ↑ "R&D Portfolio". Sanofi. http://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx.
 |  |
